Entry level $22.25 = Target price $28.00 = Stop loss $21.00 Trade the huge gap in the chart Stock is well below its average analysts price target @$31 and overweight rating. Short interest 19.87% fuel a recovery rally. Company profile Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments. The company was founded in 1990 and is headquartered in San Francisco, CA.